References
- Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–S57.
- Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol. 1999;140(2):268–272.
- Rutkowski K, Sowa P, Rutkowska-Talipska J, et al. Allergic diseases: the price of civilisational progress. Postepy Dermatol Alergol. 2014;31(2):77–83.
- Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
- FDA. Dupixent – highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf.
- Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology.
- Leitlinie (S2k) Neurodermitis Langversion Version. 2014. [atopisches Ekzem; atopische Dermatitis].
- Order of the Ministry of Health of Ukraine. No. 670 – Unified clinical protocol for 1st line, 2nd line (specialized), and 3rd line (high-specialized) medical aid in Atopic dermatitis. 2016 July 6. Available from: http://mtd.dec.gov.ua/images/dodatki/2016_670_AtopDerm/2016_670_YKPMD_AD.pdf.